Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
New Research from eBRAIN Faculty
eBRAIN Faculty Dr. Caterina Rosano points to a fascinating link between the brain and muscle health as we age. In her latest paper, Striatal Dopamine and Skeletal Muscle Energy Metabolism in Older Adults, Dr. Rosano and her team explore whether dopamine (a chemical...
